NANOVIRICIDES Aktie

>NANOVIRICIDES Aktienkurs

1.09 EUR +5.8% (Tradegate)

Ask: 1 EUR / 1991 Stück

Bid: 0.94 EUR / 2131 Stück

Tagesumsatz: 771 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>NANOVIRICIDES Performance

1 Woche: +5,3%

1 Monat: -6,8%

3 Monate: -11,4%

6 Monate: -8,0%

1 Jahr: -19,3%

laufendes Jahr: +10,1%

>NANOVIRICIDES Aktie

Name:

NANOVIRICIDES NEW DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6300873022 / A2PSNF

Symbol/ Ticker:

NV3P (Frankfurt)

Kürzel:

FRA:NV3P, ETR:NV3P, NV3P:GR

Index:

Webseite:

https://www.nanoviricides..

Profil:

Nanoviricides Inc. is a pioneering biotechnology c..
>Volltext..

Marktkapitalisierung:

22.43 Mio. EUR

Unternehmenswert:

21.47 Mio. EUR

Umsatz:

EBITDA:

-6.48 Mio. EUR

Nettogewinn:

-6.98 Mio. EUR

Gewinn je Aktie:

-0.44 EUR

Schulden:

Liquide Mittel:

0.97 Mio. EUR

Operativer Cashflow:

-6.43 Mio. EUR

Bargeldquote:

0.95

Umsatzwachstum:

Gewinnwachstum:

18.44%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NANOVIRICIDES

Letzte Datenerhebung:

12.01.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 21.57 Mio. St.

Frei handelbar: 96.66%

Leerverk. Aktien: -

Rückkaufquote: -18.51%

Mitarbeiter: 7

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 479.89%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 2.74

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -80.86%

Eigenkaprendite: -94.03%

>Peer Group

Es sind 592 Aktien bekannt.

>NANOVIRICIDES Chart & Kurs - Tradegate

>NANOVIRICIDES News

12.01.26 - 05:00	After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers (RTTNews)
	Several biotech and healthcare names posted notable gains in after-hours trading on Friday, with investors showing renewed interest in companies tied to drug development, healthcare services, and financing updates....

18.12.25 - 06:36	Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

18.12.25 - 06:36	NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 14:42	NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the dev......

17.11.25 - 15:03	NanoViricides GAAP EPS of -$0.10 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 14:42	NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarte......

14.11.25 - 14:42	NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drug......

12.11.25 - 23:06	NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase ag......

11.11.25 - 14:42	NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with ......

11.11.25 - 13:24	NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 16:00	NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 14:42	NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial o......

08.11.25 - 14:24	NanoViricides′ NV-387 shows broad antiviral potential, says Zacks (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 14:42	NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT (Accesswire)
	NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"......

03.11.25 - 14:42	NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs......

01.11.25 - 20:36	NanoViricides targets broad-spectrum virus threats – ICYMI (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.25 - 13:54	Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined S......

27.10.25 - 15:12	NanoViricides′ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 13:54	NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 (Accesswire)
	SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that t......

22.10.25 - 14:54	In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown s......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Von dem Augenblicke an, wo er das Licht der Welt erblickt, sucht ein Mensch aus ihrem Wirrwarr, in welchem auch er mit allem andern bunt durcheinander herumgewürfelt wird, sich herauszufinden und sich zu gewinnen. - Max Stirner

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram